Anders Ettrup

Anders Ettrup

Auto-generated profile, based on publicly available information

Anders Ettrup

Neurobiology Research Unit and Center for Integrated Molecular Brain Imaging (CIMBI), Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2014 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
AEAnders Ettrup
Anders Ettrup
SCSophie da Cunha-Bang
Sophie da Cunha-Bang
BMBrenda McMahon
Brenda McMahon
SLSzabolcs Lehel
Szabolcs Lehel
ADAgnete Dyssegaard
Agnete Dyssegaard
GKGitte Moos Knudsen
Gitte Moos Knudsen
[ 11 C]Cimbi-36 was recently developed as a selective serotonin 2A (5-HT2A) receptor agonist radioligand for positron emission tomography (PET) brain imaging. Such an agonist PET radioligand may provide a novel, and more functional, measure of the serotonergic system and agonist binding is more likely than antagonist binding to reflect 5-HT levels in vivo. Here, we show data from a first-in-human clinical trial with [ 11 C]Cimbi-36. In 29 healthy volunteers, we found high brain uptake and distribution according to 5-HT2A receptors with [ 11 C]Cimbi-36 PET. The two-tissue compartment model using arterial input measurements provided the most optimal quantification of cerebral [ 11 C]Cimbi-36 binding. Reference tissue modeling was feasible as it induced a negative but predictable bias in [ 11 C]Cimbi-36 PET outcome measures. In five subjects, pretreatment with the 5-HT2A receptor antagonist ketanserin before a second PET scan significantly decreased [ 11 C]Cimbi-36 binding in all cortical regions with no effects in cerebellum. These results confirm that [ 11 C]Cimbi-36 binding is selective for 5-HT2A receptors in the cerebral cortex and that cerebellum is an appropriate reference tissue for quantification of 5-HT2A receptors in the human brain. Thus, we here describe [ 11 C]Cimbi-36 as the first agonist PET radioligand to successfully image and quantify 5-HT2A receptors in the human brain.

18 October 2010 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
AEAnders Ettrup
Anders Ettrup
MPMikael Palner
Mikael Palner
NGNic Gillings
Nic Gillings
MSMartin A. Santini
Martin A. Santini
MHMartin Hansen
Martin Hansen
GKGitte Moos Knudsen
Gitte Moos Knudsen
PET brain imaging of the serotonin 2A (5-hydroxytryptamine 2A, or 5-HT2A) receptor has been widely used in clinical studies, and currently, several well-validated radiolabeled antagonist tracers are used for in vivo imaging of the cerebral 5-HT2A receptor. Access to 5-HT2A receptor agonist PET tracers would, however, enable imaging of the active, high-affinity state of receptors, which may provide a more meaningful assessment of membrane-bound receptors. In this study, we radiolabel the high-affinity 5-HT2A receptor agonist 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-[11C-OCH3]methoxybenzyl)ethanamine (11C-CIMBI-5) and investigate its potential as a PET tracer. Methods: The in vitro binding and activation at 5-HT2A receptors by CIMBI-5 was measured with binding and phosphoinositide hydrolysis assays. Ex vivo brain distribution of 11C-CIMBI-5 was investigated in rats, and PET with 11C-CIMBI-5 was conducted in pigs. Results: In vitro assays showed that CIMBI-5 was a high-affinity agonist at the 5-HT2A receptor. After intravenous injections of 11C-CIMBI-5, ex vivo rat studies showed a specific binding ratio of 0.77 ± 0.07 in the frontal cortex, which was reduced to cerebellar levels after ketanserin treatment, thus indicating that 11C-CIMBI-5 binds selectively to the 5-HT2A receptor in the rat brain. The PET studies showed that the binding pattern of 11C-CIMBI-5 in the pig brain was in accordance with the expected 5-HT2A receptor distribution. 11C-CIMBI-5 gave rise to a cortical binding potential of 0.46 ± 0.12, and the target-to-background ratio was similar to that of the widely used 5-HT2A receptor antagonist PET tracer 18F-altanserin. Ketanserin treatment reduced the cortical binding potentials to cerebellar levels, indicating that in vivo 11C-CIMBI-5 binds selectively to the 5-HT2A receptor in the pig brain. Conclusion: 11C-CIMBI-5 showed a cortex-to-cerebellum binding ratio equal to the widely used 5-HT2A antagonist PET tracer 18F-altanserin, indicating that 11C-CIMBI-5 has a sufficient target-to-background ratio for future clinical use and is displaceable by ketanserin in both rats and pigs. Thus, 11C-CIMBI-5 is a promising tool for investigation of 5-HT2A agonist binding in the living human brain.

10 January 2013 in Molecular Imaging and Biology
Verified
Journal Article
Closed access
PDF file
AEAnders Ettrup
Anders Ettrup
SHSøren Holm
Søren Holm
MHMartin Hansen
Martin Hansen
MWMuhammad Wasim
Muhammad Wasim
MSMartin Andreas Santini
Martin Andreas Santini
GKGitte Moos Knudsen
Gitte Moos Knudsen

7 March 2013 in Synapse
Verified
Journal Article
Closed access
PDF file
HHHanne Hansen
Hanne Hansen
AEAnders Ettrup
Anders Ettrup
MHMatthias M. Herth
Matthias M. Herth
ADAgnete Dyssegaard
Agnete Dyssegaard
CRCecilia Ratner
Cecilia Ratner
GKGitte Moos Knudsen
Gitte Moos Knudsen

3 December 2010 in Synapse
Verified
Journal Article
Closed access
PDF file
AEAnders Ettrup
Anders Ettrup
BKBirgitte R. Kornum
Birgitte R. Kornum
PWPia Weikop
Pia Weikop
GKGitte Moos Knudsen
Gitte Moos Knudsen

31 August 2010 in NeuroImage
Verified
Journal Article
Closed access
AEAnders Ettrup
Anders Ettrup
MHMartin Hansen
Martin Hansen
MSMartin A. Santini
Martin A. Santini
JPJames Paine
James Paine
NGNic M. Gillings
Nic M. Gillings
GKGitte M. Knudsen
Gitte M. Knudsen